Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Severe asthma patients' life is heavily influenced by the disease, which has impact on personal and professional choices or general lifestyle. Despite the available tools to help physicians investigating the patient-reported outcomes there is a need for a more standardised and structured approach to include the evaluation of quality of life together with the emotions of patients into the routine clinical interaction. We hereby report the use of an active listening and insight approach to understand the emotions of patients with severe asthma through dedicated in-person meetings involving a group of patients with their doctors, caregivers and an external moderator. The initiative "Patients insight meeting" was organized within 17 specialist referral centres for severe asthma in Italy in 2019 and involved 149 patients. Insights related to 4 different items were collected and a task force composed by the external moderators produced a general report including the suggestions from the participating centres. This experience of group-meetings involving both patients and doctors together represents an innovative way to investigate real life experience and the emotions of asthmatic patients, highlighting unmet needs related to patient's experience of his/her disease that need to be included in severe asthmatics' management strategy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491102PMC
http://dx.doi.org/10.4081/mrm.2022.854DOI Listing

Publication Analysis

Top Keywords

severe asthma
16
patients doctors
12
emotions patients
8
patients
7
severe
5
doctors group
4
group meetings
4
meetings innovative
4
innovative explore
4
explore severe
4

Similar Publications

Longer, more severe wildfire seasons are becoming the norm in fire-prone areas. Prescribed burning is a tool used to mitigate wildfire spread. However, prescribed burning also contributes to air pollution, including PM (particulate matter with aerodynamic diameter <= 2.

View Article and Find Full Text PDF

Objetives: To design the patient onboarding in a multidisciplinary severe asthma unit, according to the needs identified by patients and professionals in the unit.

Methods: Qualitative study using the human-centred design conducted between November 2022 and February 2023. Patients and professionals from the severe asthma unit and experts in the methodology participated.

View Article and Find Full Text PDF

Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry.

Respir Med

September 2025

Centre of Excellence in Treatable Traits, College of Health, Medicine and Wellbeing, University of Newcastle, New Lambton Heights, NSW, Australia; Asthma and Breathing Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia; Department of Respiratory and Sleep Medici

Background: The benefits of oral corticosteroid (OCS) stewardship approaches -including monoclonal antibody treatments for severe asthma- on reducing toxic OCS exposure and related comorbidities such as depression and anxiety require real-world evaluation.

Methods: This real-world observational study investigated OCS exposure and associated complications over 24 months in patients enrolled in the Australian Mepolizumab Registry (n=412).

Results: Patients were median age 59 years, 58% were female.

View Article and Find Full Text PDF

Emerging systemic treatments for asthma and allergic diseases: New tricks, same dog?

J Allergy Clin Immunol Pract

September 2025

Associate Professor of Medicine, Medical Director of Clinical Asthma Research, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center. Electronic address:

Asthma and allergic diseases are heterogeneous conditions driven by complex immunological pathways, with type 2 (T2) inflammation being a key but not exclusive component. Advances in immunology have spurred interest in a breadth of mechanisms and innovative therapeutic strategies, including novel targets, extended dosing intervals, and combined-target therapies. This clinical commentary provides a critical overview of ongoing clinical trials and emerging evidence supporting the use of these therapies in asthma and other allergic conditions.

View Article and Find Full Text PDF

Background: High doses of maintenance inhaled corticosteroids (ICS) in asthma may achieve only modest additional clinical benefit beyond low-to-medium doses and are associated with an increased risk of adverse systemic effects. The ICS dose-response relationship when administered as maintenance combination ICS/long-acting beta-agonist (LABA) therapy is uncertain.

Research Question: What is the ICS dose-response of maintenance ICS/LABA therapy?

Methods: A systematic review of randomized controlled trials (RCTs) allocating participants to >1 ICS dose category, per Global Initiative for Asthma categorization, administered in combination ICS/LABA inhalers was conducted.

View Article and Find Full Text PDF